871936-97-9

Basic information

• Product Name: 3-benzyloxy-2-[4-fluorobenzyl(methyl)aminocarbonyl]-5-methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine
• Synonyms: 3-benzyloxy-2-[4-fluorobenzyl(methyl)aminocarbonyl]-5-methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine
• CAS NO: 871936-97-9
• Molecular Weight: 422.459
• Mol File: 871936-97-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-benzyloxy-2-[4-fluorobenzyl(methyl)aminocarbonyl]-5-methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-benzyloxy-2-[4-fluorobenzyl(methyl)aminocarbonyl]-5-methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine(871936-97-9)
• EPA Substance Registry System: 3-benzyloxy-2-[4-fluorobenzyl(methyl)aminocarbonyl]-5-methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine(871936-97-9)

Safety Data

• Hazardous Substances Data: 871936-97-9(Hazardous Substances Data)

Upstream product

• 871936-51-5 dimethyl 1-(2-azidoethyl)-4-benzyloxy-1H-pyrazole-3,5-dicarboxylate 
• 871937-42-7 methyl 3-(benzyloxy)-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxylate 
• 871936-50-4 dimethyl 4-benzyloxy-1-(2-bromoethyl)-1H-pyrazole-3,5-dicarboxylate 
• 871936-95-7 methyl 3-(benzyloxy)-5-methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxylate 
• 933984-70-4 dimethyl 4-(benzyloxy)-1H-pyrazole-3,5-dicarboxylate 
• 871936-96-8 3-benzyloxy-5-methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxylic acid 
• 405-66-3 (4-Fluoro-benzyl)-methyl-amine 

Relevant articles and documents

HIV INTEGRASE INHIBITORS

Bicyclic pyrazoles of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: (I), wherein Z is O or N(R8); n is an integer equal to zero or 1; and R1, R2, R3, R4, R5, R6, R7 and R8 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.